// App-Quantinova.ai

Abstract 11180 : Contemporary Evidence on Risk Stratification of Anticoagulated Non-Valvular Atrial Fibrillation Patients Grouped by Cha2D2-vasc Score Levels

Researchers

Presenter

  • Gregory Y Lip

Principal Investigators

  • Richard Murphy

  • Farhad Sahiar

  • Amol Dhamane

  • Mauricio Ferri

  • Patrick Hlavacek

  • Madison Preib

  • Allison Keshishian

  • Cristina Russ

  • Lisa Rosenblatt

  • Steve Deitelzweig

Medical Centers

  • Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom

  • Bristol-Myers Squibb, Lawrenceville, NJ

  • STATinMED Research, Ann Arbor, MI

  • FAA/Civil Aerospace Med Institute, Oklahoma City, OK

  • Ochsner Clinic Foundation, New Orleans, LA

  • Pfizer Inc, New York, NY

Locations

  • United Kingdom

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Cardiovascular (CVS)

Disease

  • Non-valvular atrial fibrillation

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

  • Edoxaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved